The Use of Heterologous Antigens for Biopanning Enables the Selection of Broadly Neutralizing Nanobodies Against SARS-CoV-2
Authors:
- Vazirbek S. AripovVAVazirbek S. Aripov
- Anna V. ZaykovskayaAZAnna V. Zaykovskaya
- Ludmila V. MechetinaLMLudmila V. Mechetina
- Alexander M. NajakshinANAlexander M. Najakshin
- Alexander A. BondarABAlexander A. Bondar
- Sergey G. ArkhipovSASergey G. Arkhipov
- Egor A. MustaevEMEgor A. Mustaev
- Margarita G. IlyinaMargarita G. Ilyina
- Sophia S. BorisevichSophia S. Borisevich
- Alexander A. IlyichevAIAlexander A. Ilyichev
- Valentina S. NesmeyanovaVNValentina S. Nesmeyanova
- Anastasia A. IsaevaAIAnastasia A. Isaeva
Open Access
- 7 March 2025
- journal article
- research article
- Published by MDPI AG in Antibodies
- Vol. 14 (1) , 23
Abstract
Background: Since the emergence of SARS-CoV-2 in the human population, the virus genome has undergone numerous mutations, enabling it to enhance transmissibility and evade acquired immunity. As a result of these mutations, most monoclonal neutralizing antibodies have lost their efficacy, as they are unable to neutralize new variants. Antibodies that neutralize a broad range of SARS-CoV-2 variants are of significant value in combating both current and potential future variants, making the identification and development of such antibodies an ongoing critical goal. This study discusses the strategy of using heterologous antigens in biopanning rounds. Methods: After four rounds of biopanning, nanobody variants were selected from a phage display library. Immunochemical methods were used to evaluate their specificity to the S protein of various SARS-CoV-2 variants, as well as to determine their competitive ability against ACE2. Viral neutralization activity was analyzed. A three-dimensional model of nanobody interaction with RBD was constructed. Results: Four nanobodies were obtained that specifically bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein and exhibit neutralizing activity against various SARS-CoV-2 strains. Conclusions: The study demonstrates that performing several rounds of biopanning with heterologous antigens allows the selection of nanobodies with a broad reactivity spectrum. However, the fourth round of biopanning does not lead to the identification of nanobodies with improved characteristics.Keywords
Funding Information
- State Research Center of Virology and Biotechnology VECTOR (State assignment 23/21)
This publication has 46 references indexed in Scilit:
- Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamstersAntiviral Research, 2023
- Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent modelsVirologica Sinica, 2023
- Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2Journal of Biological Chemistry, 2023
- Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronavirusesBiomedical Engineering Advances, 2022
- Superimmunity by pan-sarbecovirus nanobodiesCell Reports, 2022
- A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapyAntiviral Research, 2022
- OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical SpaceJournal of Chemical Theory and Computation, 2021
- Single‐Domain Antibodies and Their UtilityCurrent Protocols in Immunology, 2013
- PIPER: An FFT‐based protein docking program with pairwise potentialsProteins: Structure, Function, and Bioinformatics, 2006
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996